PR Newswire Clinical TrialsOriginal article
AbelZeta Receives EMA PRIME Designation for C-CAR168 in Lupus Nephritis and Systemic Lupus Erythematosus
RegulatoryC-CAR168Positive
AI Analysis
Summary
AbelZeta Pharma announced receipt of EMA PRIME designation for C-CAR168, a cell-based therapeutic product, for the treatment of lupus nephritis and systemic lupus erythematosus. PRIME designation expedites the EMA review process for promising therapies.
Outcome Details
EMA PRIME Designation granted
Importance:7/10
Sentiment:
0.80
EMA PRIMEcell therapylupus nephritissystemic lupus erythematosusregulatory milestone
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 20, 2026 2:19 PM